Obesity

  • Effective but inaccessible antiobesity medications
    Sima Saberi, MD, Sabiha M. Hussain, MD, Mohammad Kazem Fallahzadeh, MD, MAS, Hector Madariaga, MD, Pooja Budhiraja, MBBS and Kenneth J. Woodside, MD
    Cleveland Clinic Journal of Medicine March 2025, 92 (3) 141; DOI: https://doi.org/10.3949/ccjm.92c.03001
  • Hypoglycemia after bariatric surgery: Management updates
    CME article
    Anira Iqbal, MD and Vinni Makin, MBBS, MD
    Cleveland Clinic Journal of Medicine February 2025, 92 (2) 103-108; DOI: https://doi.org/10.3949/ccjm.92a.24033

    The authors discuss how to differentiate post-bariatric surgery hypoglycemia from other causes of hypoglycemia, highlight the evolving role of continuous glucose monitors in detecting it, and summarize management options.

  • Effective but inaccessible antiobesity medications: A call for sharing responsibility for improving access to evidence-based care
    Bartolome Burguera, MD, PhD, Marcio L. Griebeler, MD and W. Timothy Garvey, MD
    Cleveland Clinic Journal of Medicine November 2024, 91 (11) 671-676; DOI: https://doi.org/10.3949/ccjm.91a.24068

    The potentially transformative benefits of second-generation obesity medications have yet to be realized because many patients lack access to these medications.

  • Born again: The many lives of metformin
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine September 2023, 90 (9) 523-524; DOI: https://doi.org/10.3949/ccjm.90b.09023

    Repurposing old drugs for new indications is not a new drug-development strategy.

  • Should I consider metformin therapy for weight loss in patients with obesity but without diabetes?
    Paloma Rodriguez, MD, Kevin M. Pantalone, DO, ECNU, FACE, Marcio L. Griebeler, MD and Bartolome Burguera, MD, PhD
    Cleveland Clinic Journal of Medicine September 2023, 90 (9) 545-548; DOI: https://doi.org/10.3949/ccjm.90a.22096

    The authors appraise the evidence to date for weight loss with metformin in this patient population.

  • Antiobesity drug therapy
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 657; DOI: https://doi.org/10.3949/ccjm.88c.12001
  • Physician resistance to obesity pharmacotherapy
    Vania Modesto-Lowe, MD, Allison Wick, BS and Michael Dang, BS, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 658; DOI: https://doi.org/10.3949/ccjm.88c.12003
  • In Reply: Antiobesity drug therapy
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta Kashyap, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 657-658; DOI: https://doi.org/10.3949/ccjm.88c.12002
  • In Reply: Physician resistance to obesity pharmacotherapy
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta Kashyap, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 658-659; DOI: https://doi.org/10.3949/ccjm.88c.12004
  • Antiobesity drug therapy: An individualized and comprehensive approach
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta R. Kashyap, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 440-448; DOI: https://doi.org/10.3949/ccjm.88a.20080

    As part of a comprehensive plan, these drugs can provide lasting obesity control and additional health benefits, including decreased cardiovascular risk.

Pages